ReviewExpert reviews in molecular medicine2025
Role of S100 family proteins in colorectal cancer (CRC): an overview of their potential function as new biomarkers and therapeutic agents.
Review in Expert reviews in molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Lactylation-driven stabilization of the S100A11/ANXA2 complex promotes pancreatic cancer metastasis.Cell biology and toxicology · 2026Article
- Lactylation shields S100A11 from degradation to promote gastric cancer metastasis.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- From heterogeneity to mechanism: a systems-level analysis pinpoints the S100A8/A9 axis in colorectal cancer.Cancer cell international · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Colorectal cancer (CRC) is the second deadliest cancer worldwide, posing a great threat to human health and a social burden. Various genetic and epigenetic alterations can activate tumourigenesis-related signalling pathways, leading to CRC development and progression. Over the past two decades, the understanding of the role of S100 family proteins in different types of cancer has received great attention. S100 proteins, as intracellular and extracellular, play important roles in regulating various cellular processes, such as calcium homeostasis, apoptosis, tumour cell proliferation, invasion and motility. It is well documented that alteration in expression of S100 proteins can be associated with tumourigenesis and cancer progression. These proteins play important roles in CRC carcinogenesis by activating different signalling pathways, especially the nuclear factor kappa B (NF-κB) signalling pathway, which is involved in cell proliferation, invasion and migration. In this review, we describe the functions of S100 proteins in the context of inflammation, tumourigenesis, cancer progression, metastasis, and drug resistance in CRC. We also discuss the potential of targeting different S100 proteins as prognostic factors and therapeutic agents for CRC treatment. This narrative review will increase our understanding of the role of S100 proteins in the progression of CRC and provide insights into the use of S100 proteins as new biomarkers and therapeutic targets for CRC therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.